


# WELCOME

---



## Clozapine & LAI Virtual Forum

June 2024 | 4:00 – 4:45 pm ET

The Clozapine & LAI Virtual Forum is an all-new, peer-to-peer, interactive dialogue between psychiatrists, nurse practitioners, and other prescribing clinicians.

It is informal, no registration required — just join our Zoom call and share your challenges and questions on the month's trending topic around either clozapine or LAIs.

### TODAY'S TOPIC:

## Therapeutic Drug Monitoring (TDM) for Antipsychotic Medications



# MODERATORS

---

## **Robert Cotes, MD**

SMI Adviser Physician Expert; Emory University

Dr. Robert Cotes, MD, is an Associate Professor at Emory University School of Medicine in the Department of Psychiatry and Behavioral Sciences. He has interest in clozapine, characterizing persistent symptoms of schizophrenia, understanding cardiometabolic side effects of antipsychotic medications, and first episode psychosis.

## **Donna Rolin, PhD, APRN**

SMI Adviser Nursing Expert; University of Texas, Austin

Dr. Donna Rolin is Clinical Associate Professor and the Director of the Psychiatric Mental Health Nurse Practitioner program at the University of Texas with 23 years of experience in psychiatric nursing, including inpatient, community, forensic, and older adult settings.

## **Megan Ehret, PharmD, MS, BCPP**

SMI Adviser Pharmacy Consultant, University of Maryland

Dr. Megan Ehret is a Professor at University of Maryland School of Pharmacy in the Department of Practice, Sciences, and Health Outcomes Research and is Co-Director of the Mental Health Program. She is a Past-President of the American Association of Psychiatric Pharmacists. Her current interests include psychotropic medication adherence and the incorporation of the psychiatric pharmacist in practice.

## Discussion Questions for Virtual Forum:

---

- Do you systematically measure antipsychotic therapeutic drug levels? If so, how often?
- Which agents do you obtain levels for?
- When do you consider obtaining the levels?
  - Steady-state
  - Changing doses
- What about obtaining levels with long-acting injectable antipsychotics?

# General Clinical Indications

---

- Understanding poor response: Poor adherence vs. treatment resistance
- Understanding poor tolerability: high sensitivity to antipsychotic adverse effect or supratherapeutic doses
- Establishing dose: titrations, lowest effective dose, “benchmarking”

# Specific Clinical Indications

- Suspected treatment resistance
- Suspected unusual pharmacokinetics
  - Drug-drug interactions
  - Medical comorbidities
  - Pregnancy
  - Age
- Genetic Factors
- Change in tobacco smoking status
- Non-adherence

# Consensus Paper: Levels of Evidence

- Level 1:
  - Fluphenazine, haloperidol, Perphenazine, olanzapine, clozapine

Schoetsanis G et al. Blood levels to optimize antipsychotic treatment in clinical practice; a joint consensus of the American Society of Clinical Psychopharmacology (ASCP) and the therapeutic drug monitoring (TDM) task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP).  
Journal of Clinical Psychiatry

# Practical Issues

- Timing of draw: Steady-state
- Oral medications: Before the morning dose, if a morning dose is given
- LAIs: Right before the next injection is due

# Therapeutic Reference Range


Drugs and Active Metabolite	Therapeutic Reference Range (ng/mL)	Laboratory Alert Level (ng/mL)
Clozapine	350-600	1,000
Fluphenazine	1-10	15
Haloperidol	1-10	15
Perphenazine	0.6-2.4	5
Olanzapine	20-80	100
Aripiprazole	100-350	1,000
Paliperidone	20-60	120
Risperidone + 9-hydroxyrisperidone	20-60	120

Schoresanitis G et al. Blood levels to optimize antipsychotic treatment in clinical practice; a joint consensus of the American Society of Clinical Psychopharmacology (ASCP) and the therapeutic drug monitoring (TDM) task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). Journal of Clinical Psychiatry



# FEEDBACK

Please help us improve the Clozapine & LAI Virtual Forum by completing this survey:  
<http://smiadviser.org/forumfeedback>



An APA and SAMHSA Initiative

